Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Dual GLP-1/GIP receptor activation providing broader metabolic benefits than conventional GLP-1 therapies.
Produced in the USA at a GMP facility
Retatrutide is an investigational triple incretin receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
Here is what an actual prospective patient encounters
The outcome represents a win for Health Secretary Robert F Kennedy Jr., who has publicly supported peptide therapies, and the broader wellness and longevity industry, which stands to profit substantially
US$ 22.85
US$ 25.85
US$ 23.36
US$ 23.07
US$ 26.20
US$ 20.62
US$ 21.42
